Individual estimates of age at detectable amyloid onset for risk factor assessment

Alzheimer's and Dementia

Volumn 12, Issue 4, 2016, Pages 373-379

  Bilgel, Murat ^a,b   An, Yang ^a   Zhou, Yun ^c   Wong, Dean F ^c   Prince, Jerry L ^b,c,d   Ferrucci, Luigi ^a   Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Johns Hopkins University School of Medicine   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d Whiting School of Engineering   (United States)

Author keywords

Age at onset; Amyloid imaging; APOE; PET; Pittsburgh compound B

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

AGED; ARTICLE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; AGING; BRAIN; DIAGNOSTIC IMAGING; EDUCATIONAL STATUS; GENETICS; HETEROZYGOTE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; EDUCATIONAL STATUS; FEMALE; HETEROZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; SEX CHARACTERISTICS; THIAZOLES;

EID: 84961195794     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.08.166     Document Type: Article

References (43)

1. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, and et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
2. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study Lancet Neurol 12 2013 357 367
3. E.H. Corder, L. Lannfelt, N. Bogdanovic, L. Fratiglioni, and H. Mori The role of APOE polymorphisms in late-onset dementias Cell Mol Life Sci 54 1998 928 934
4. C.-C. Liu, T. Kanekiyo, H. Xu, and G. Bu Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy Nat Rev Neurol 9 2013 106 118
5. 11C]Pittsburgh compound B data Ann Neurol 70 2011 857 861
6. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, and et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 6820 6825
7. A.S. Fleisher, K. Chen, X. Liu, N. Ayutyanont, A. Roontiva, P. Thiyyagura, and et al. Apolipoprotein E ϵ4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 34 2013 1 12
8. J. Sojkova, Y. Zhou, Y. An, M.A. Kraut, L. Ferrucci, D.F. Wong, and et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults Arch Neurol 68 2011 644 649
9. V.L. Villemagne, K.E. Pike, G. Chételat, K.A. Ellis, R.S. Mulligan, P. Bourgeat, and et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease Ann Neurol 69 2011 181 192
10. P. Vemuri, H.J. Wiste, S.D. Weigand, D.S. Knopman, L.M. Shaw, J.Q. Trojanowski, and et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Ann Neurol 67 2010 308 316
11. J.C. Morris, C.M. Roe, C. Xiong, A.M. Fagan, A.M. Goate, D.M. Holtzman, and et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging Ann Neurol 67 2010 122 131
12. M. Fouquet, F.L. Besson, J. Gonneaud, R. La Joie, and G. Chételat Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan Neuropsychol Rev 24 2014 290 299
13. W.J. Jagust, and S.M. Landau Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging J Neurosci 32 2012 18227 18233
14. K.R. Murphy, S.M. Landau, K.R. Choudhury, C.A. Hostage, K.S. Shpanskaya, H.I. Sair, and et al. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth Neuroimage 78 2013 474 480
15. C.A. Mathis, L.H. Kuller, W.E. Klunk, B.E. Snitz, J.C. Price, L.A. Weissfeld, and et al. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects Ann Neurol 73 2013 751 761
16. A.L. Hinrichs, M.A. Mintun, D. Head, A.M. Fagan, D.M. Holtzman, J.C. Morris, and et al. Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease Biol Psychiatry 67 2010 581 583
17. K. Kantarci, V. Lowe, S.A. Przybelski, S.D. Weigand, M.L. Senjem, R.J. Ivnik, and et al. APOE modifies the association between Aβ load and cognition in cognitively normal older adults Neurology 78 2012 232 240
18. C. Roe, A. Fagan, E. Grant, J. Hassenstab, K. Moulder, D.M. Dreyfus, and et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later Neurology 80 2013 1784 1791
19. E.C. Mormino, R.A. Betensky, T. Hedden, A.P. Schultz, A. Ward, W. Huijbers, and et al. Amyloid and APOE ϵ4 interact to influence short-term decline in preclinical Alzheimer disease Neurology 82 2014 1760 1767
20. 11C-PIB uptake is associated with age, APOE genotype, and gender in "healthy aging." J Alzheimers Dis 41 2014 193 202
21. S.M. Resnick, M. Bilgel, A. Moghekar, Y. An, Q. Cai, M.C. Wang, and et al. Longitudinal changes in Aβ biomarkers and associations with APOE genotype in two longitudinal cohorts Neurobiol Aging 36 2015 2333 2339
22. C.R. Jack, H.J. Wiste, S.D. Weigand, D.S. Knopman, P. Vemuri, M.M. Mielke, and et al. Age, sex, and APOE ϵ4 effects on memory, brain structure, and β-amyloid across the adult life span JAMA Neurol 72 2015 511 519
23. W.J. Jansen, R. Ossenkoppele, D.L. Knol, B.M. Tijms, P. Scheltens, F.R.J. Verhey, and et al. Prevalence of cerebral amyloid pathology in persons without dementia JAMA 313 2015 1924 1938
24. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337 1342
25. M. Thambisetty, Y. An, and T. Tanaka Alzheimer's disease risk genes and the age-at-onset phenotype Neurobiol Aging 34 2013 2696.e1 2696.e5
26. A.C. Naj, G. Jun, C. Reitz, B.W. Kunkle, W. Perry, Y.S. Park, and et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study JAMA Neurol 71 2014 1394 1404
27. A.S. Khachaturian, C.D. Corcoran, L.S. Mayer, P.P. Zandi, and J.C.S. Breitner Apolipoprotein E ϵ4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility Arch Gen Psychiatry 61 2004 518 524
28. S.M. Resnick, A.F. Goldszal, C. Davatzikos, S. Golski, M.A. Kraut, E.J. Metter, and et al. One-year age changes in MRI brain volumes in older adults Cereb Cortex 10 2000 464 472
29. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R 3rd ed., revised 1987 American Psychiatric Association Washington, DC
30. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
31. M. Jenkinson, P. Bannister, M. Brady, and S. Smith Improved optimization for the robust and accurate linear registration and motion correction of brain images Neuroimage 17 2002 825 841
32. B.B. Avants, P. Yushkevich, J. Pluta, D. Minkoff, M. Korczykowski, J. Detre, and et al. The optimal template effect in hippocampus studies of diseased populations Neuroimage 49 2010 2457 2466
33. Jog A, Roy S, Carass A, Prince JL. Magnetic resonance image synthesis through patch regression. IEEE 10th Int. Symp. Biomed. Imaging, San Francisco, CA, USA: 2013, p. 350-353.
34. R.S. Desikan, F. Ségonne, B. Fischl, B.T. Quinn, B.C. Dickerson, D. Blacker, and et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest Neuroimage 31 2006 968 980
35. B.B. Avants, C.L. Epstein, M. Grossman, and J.C. Gee Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain Med Image Anal 12 2008 26 41
36. 11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease Neuroimage 36 2007 298 312
37. J.E. Hixson, and D.T. Vernier Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with with Hhal J Lipid Res 31 1990 545 548
38. K.M. Rodrigue, K.M. Kennedy, M.D. Devous Sr., J.R. Rieck, A.C. Hebrank, R. Diaz-Arrastia, and et al. β-amyloid burden in healthy aging Neurology 78 2012 387 395
39. K.A. Johnson, R.A. Sperling, C.M. Gidicsin, J.S. Carmasin, J.E. Maye, R.E. Coleman, and et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging Alzheimers Dement 9 2013 S72 S83
40. M.R. Meyer, J.T. Tschanz, M.C. Norton, K.A. Welsh-Bohmer, D.C. Steffens, B.W. Wyse, and et al. APOE genotype predicts when -not whether- one is predisposed to develop Alzheimer disease Nat Genet 19 1998 321 322
41. C.R. Jack, H.J. Wiste, T.G. Lesnick, S.D. Weigand, D.S. Knopman, V.S. Pankratz, and et al. Brain beta-amyloid load approaches a plateau Neurology 80 2013 890 896
42. F. Yasuno, H. Kazui, N. Morita, K. Kajimoto, M. Ihara, A. Taguchi, and et al. Low amyloid-β deposition correlates with high education in cognitively normal older adults: A pilot study Int J Geriatr Psychiatry 30 2015 919 926
43. J.E. Eichner, S.T. Dunn, G. Perveen, D.M. Thompson, K.E. Stewart, and B.C. Stroehla Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review Am J Epidemiol 155 2002 487 495